Sentences with phrase «stage cancer clinical»
FAK inhibitors are being tested on their own in early stage cancer clinical trials, but it will be some years before it is known if combining these drugs with BRAF inhibitors could help patients.
https://www.sciencedaily.com/ Not exact matches
Eleven, based in Cambridge, Mass., is going to continue developing Viventia's two main cancer drugs, one of which is in Stage 3 clinical trials.
HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.
But a late - stage clinical trial called CheckMate - 026 for the drug failed to meet its primary goal of halting cancer progression in advanced, untreated patients whose tumors consisted of at least 5 % PD - L1.
HOUSTON, April 17, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $ 7.50 per share.
HOUSTON, April 16, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock.
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders.
Sierra Oncology, Inc., a clinical stage drug development company focused on advancing next - generation DNA damage response therapeutics for the treatment of patients with cancer, went public near $ 29 in July 2015, then began a downtrend that continued through a June 2017 all - time low of $ 1.10.
BioNTech hit the headlines in July when its experimental personalized cancer vaccine, tailored to the tumors of individual patients, kept disease in check in an early - stage clinical trial.
Maastricht, The Netherlands, 1 November 2017 — Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a Phase 1b...
Participants in the study included 588 men diagnosed with intermediate risk prostate cancer (i.e., clinical stage T1c - T2b) and enrolled in the trial between 2003 and 2012.
Professor Arnie Purushotham, Cancer Research UK's senior clinical adviser, said: «One of the challenges when treating early stage breast cancer is trying to minimise the side effects that can have a real impact on a woman's life, without affecting the chances of curinCancer Research UK's senior clinical adviser, said: «One of the challenges when treating early stage breast cancer is trying to minimise the side effects that can have a real impact on a woman's life, without affecting the chances of curincancer is trying to minimise the side effects that can have a real impact on a woman's life, without affecting the chances of curing her.
As Scientific American reported earlier this year, more than half of the current cancer clinical trials do incorporate some form of immunotherapy but still oncologists are often only in the early stages of understanding how to use such treatment on a larger scale.
They gauged aggressiveness using the results of the patients» prostate cancer - specific antigen, or PSA, tests, as well as the clinical stage of their cancer and Gleason grade.
Scientists at The Institute of Cancer Research, London, analysed 177 tumour samples from patients with stage I non-seminomatous tumours enrolled in clinical trials through the Medical Research Council (MRC) Clinical Triaclinical trials through the Medical Research Council (MRC) Clinical TriaClinical Trials Unit.
Several years ago, for example, poor chemical probe data led researchers to pursue a final stage clinical trial on a cancer drug candidate called iniparib.
Compared to patients with low - risk disease, those with intermediate - risk cancer (PSA > 10ng / ml or Gleason score 7 or clinical stage T2b / 2c) had a nearly four-fold higher chance of dying from prostate cancer within 15 years.
Dr. Sparano continued: «This is the first prospectively conducted clinical trial evaluating this assay — or any multigene expression assay for that matter — in which patients with early stage breast cancer were uniformly treated based on their assay results.
A drug used to treat men with late - stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (Cancer Institute at Oregon Health & Science University (OHSU).
The findings provide the highest level of evidence supporting expert - derived clinical practice guidelines which have recommended Oncotype DX in patients with early stage ER - positive breast cancer.
«The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk - stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medcancer, and indicate that the findings are generalizable to everyday clinical practice,» said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of MedCancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.
In the 1980s, both US - based and international randomized clinical studies found that BCT and mastectomy offered women with early stage breast cancer equal survival benefit.
«The good news is that this finding predicts that patients missing either gene should be sensitive to new therapies targeting focal adhesion enzymes, which are currently being tested in early - stage clinical trials,» says Shaw, who is also a member of the Moores Cancer Center and an adjunct professor at the University of California, San Diego.
«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»
Partnering with the U.S. Food and Drug Administration allowed Doebele and colleagues to access clinical trial data describing initial tumor response, PFS and OS for 305 patients with stage IIIb or IV non-small cell lung cancer on trials of ALK inhibitors and 355 similar patients on trials of immunotherapies directed at PD - 1.
But this is early laboratory research and the next stage is for clinical trials to confirm whether resveratrol has the same effects in people at high risk of bowel cancer.»
«Cancer is like a person's thumbprint; each person's cancer is uniquely theirs,» says Bill Hearl, CEO of Immunomic Therapeutics, a clinical stage biotechnology company developing a nucleic acid immunotherapy platform with the potential to treat cancer, allergies and animal health iCancer is like a person's thumbprint; each person's cancer is uniquely theirs,» says Bill Hearl, CEO of Immunomic Therapeutics, a clinical stage biotechnology company developing a nucleic acid immunotherapy platform with the potential to treat cancer, allergies and animal health icancer is uniquely theirs,» says Bill Hearl, CEO of Immunomic Therapeutics, a clinical stage biotechnology company developing a nucleic acid immunotherapy platform with the potential to treat cancer, allergies and animal health icancer, allergies and animal health issues.
The study, a retrospective survival analysis, included 229 patients who participated in two randomized, controlled clinical trials focused on relief of constipation for patients receiving palliative care for various types of late - stage cancer and other terminal diseases.
Syndax Pharmaceuticals, Inc. («Syndax,» the «Company» or «we»)(Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX - 6352 in multiple cancer indications, in collaboration with The Wistar Institute and Indiana University Melvin and Bren Simon Cancer Center, today announced the publication of a preclinical report demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (Mcancer indications, in collaboration with The Wistar Institute and Indiana University Melvin and Bren Simon Cancer Center, today announced the publication of a preclinical report demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MCancer Center, today announced the publication of a preclinical report demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).
The racially diverse study sample consisted of two groups: 89 patients diagnosed with low risk prostate cancer (clinical stage T1 - T2a, biopsy Gleason score 6 or less, and prostate specific antigen less than 10 ng / ml), who initially underwent AS, and 420 patients without cancer who had a negative prostate needle biopsy.
Notably, multiple Notch inhibitors are in various stages of clinical development as potential cancer therapies.
About VentiRx VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll - like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases.
ura Oncology Inc., a clinical stage biopharmaceutical company that develops therapies for cancer patients, is now trading on the NASDAQ after an initial public offering.
NEW YORK AND SAN DIEGO (Sept. 3, 2014)-- The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX - 2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships.
In an article published in the Journal of Clinical Oncology (https://doi.org/10.1200/JCO.2017.74.6586), Laenkholm et al report on a study of 2,558 postmenopausal women identified as having HR positive / HER2 - negative, early - stage breast cancer, 1,395 of whom had one to three positive axillary nodes.
For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply
As a Wallenberg Clinical Scholar, Richard Rosenquist Brandell will use the infrastructure for large - scale investigation of cells and their genetic material at SciLifeLab to systematically study blood cancer cells from different groups of patients and stages of the disease.
The ultimate goal is to develop new and better approaches for genetic engineering of stem cells to be tested within a clinical trial for the treatment of late stage advanced cancers.
Lentiviral vectors are promising agents for cancer immunotherapy, but this research is still in the pre - clinical / early clinical stages.
There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.
The NCTN — which will focus on early and late stage clinical trials for adults with cancer — will consist of fewer but larger groups of investigators and will distribute resources in a more effective way.
The availability of such clinical samples spearheaded a major research effort to define the stages of cervical cancer progression.
Production of CCS1477 in capsule form is now complete, ahead of forthcoming first - in - human clinical trials to investigate the novel drug's tolerability and efficacy in treating late stage prostate cancer (CRPC).
Immune Design is a clinical - stage biotechnology company made up of collaborative, «can do», experienced professionals passionate about leveraging the company's leading - edge technologies that target dendritic cells for a more precise immune response for the treatment of cancer and other chronic conditions.
CRI researchers analyzed NY - ESO - 1 cancer - testis (CT) antigen expression in esophageal cancer and have sought to correlate this expression with disease stage and clinical outcome.
Through basic and clinical biomedical research and training, NCI conducts and supports research that will lead to a future in which we can prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we can not eliminate so they become manageable, chronic diseases.
For example, the translational laboratory is providing support to a precision medicine - based clinical trial for patients with early - stage, triple - negative breast cancer.
In one eye - opening review of recent research, Charles Drake, M.D., Ph.D., of Johns Hopkins, who is also a member of CRI's clinical trials network, discussed several cancer vaccines that are making progress, including coxsackievirus A21, an oncolytic virus vaccine being studied in late stage melanoma, and NewLink's algenpantucel - L in pancreatic cancer (HyperAcute ® pancreas).
Apexigen is a clinical - stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno - oncology agents that could harness the patient's immune system to combat and eradicate cancer.
Read more about the Pancreatic Cancer Research Center including clinical trials that are available for all stages of pancreatic cCancer Research Center including clinical trials that are available for all stages of pancreatic cancercancer.